A United States cost-benefit comparison of an apodized, diffractive, presbyopia-correcting, multifocal intraocular lens and a conventional monofocal lens
| Autor: | Anna O. D'Souza, Brian L. Meissner, Kendra Hileman, Curtis Waycaster, William A. Maxwell |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Refractive error Financing Personal genetic structures medicine.medical_treatment Cost-Benefit Analysis Intraocular lens law.invention Quality of life Cost of Illness Lens Implantation Intraocular law medicine Humans Aged Lenses Intraocular Cost–benefit analysis business.industry Presbyopia Multifocal intraocular lens medicine.disease eye diseases Sensory Systems United States Lens (optics) Clinical trial Ophthalmology Quality of Life Optometry Surgery Female sense organs business |
| Zdroj: | Journal of cataract and refractive surgery. 34(11) |
| ISSN: | 0886-3350 |
| Popis: | PURPOSE: To demonstrate the value, from the patient's perspective, of an apodized, diffractive, presbyopia-correcting multifocal intraocular lens (MF-IOL) compared to a conventional monofocal intraocular lens (CM-IOL). SETTING: Open-label, multi-site U.S. clinical trial. METHODS: A cost-benefit analysis was conducted using cataract patients' willingness-to-pay (WTP) for spectacle independence as the measure of economic benefit. WTP was elicited from participants in a clinical trial comparing a MF-IOL and a CM-IOL. Costs borne by patients were obtained from standard reference sources. A 14-year analytical timeframe was used, and a 3% annual discount rate was applied to both costs and benefits. The outcome of interest was net benefit (difference between benefits and costs). A probabilistic sensitivity analysis was used to confirm the robustness of the economic results. RESULTS: Four hundred ninety-five patients provided WTP estimates for spectacle independence (MF-IOL, n = 339; CM-IOL, n = 156). Eighty percent of all patients were willing to pay at least $5 per day to be spectacle independent. The incremental acquisition cost associated with bilateral implantation of 2 MF-IOLs was estimated at $4,000. Eighty percent in the MF-IOL group and 8% in the CM-IOL group reported post-operative spectacle independence. The net benefit was $11,670 in the MF-IOL group and $155 in the CM-IOL group. The probabilistic sensitivity analysis confirmed the robustness of the economic outcomes. CONCLUSION: The net benefit of the MF-IOL exceeded its acquisition cost and the net benefit of the CM-IOL, demonstrating its value to select cataract patients willing to pay a premium for spectacle independence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|